Anti-tumour necrosis factor (TNF)-α inhibitors (TNFi) are the most used therapeutic agents for non-systemic JIA refractory to cDMARD therapy, due to their proven efficacy across various JIA subtypes [65]. Here, TNF is linked to juvenile idiopathic arthritis.